Ankylosing Spondylitis Bekhterevs Disease Epidemiology Forecast

DelveInsight’s ‘Ankylosing Spondylitis (AS)—Epidemiology Forecast–2032’ report delivers an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS trends in the 7MM countries.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Ankylosing Spondylitis (AS) Disease Understanding

Ankylosing Spondylitis (AS) also called as Bechterew's disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women. General onset of AS commonly occurs in younger people, between the ages of 17 and 45. However, it can also affect children and those who are much older (Spondylitis association of america).

 

AS is a type of spondyloarthropathy (SpA)—Spondyloarthropathies are a family of related inflammatory rheumatic disorders which also include reactive arthritis (RA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease—and is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. It has also been found that such patients quite often have a family history of either AS or another spondyloarthropathy. Axial Spondyloarthritis or axial SpA (axSpA) refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain. Axial SpA is further divided into two subgroups as Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Continued in the report…..

Ankylosing Spondylitis (AS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Ankylosing Spondylitis, Diagnosed Prevalent cases of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis scenario in the the 7MM countries from 2019 to 2032.

Ankylosing Spondylitis (AS) Detailed Epidemiology Segmentation

  • Total prevalent population of AS in seven major markets is 2,282,664 in 2021. These cases are estimated to increase in the forecast period 
  • As per the estimates there were nearly 968,326 AS cases in EU-5 countries in 2021. Germany accounted for the highest number of cases in 2021, followed by Spain and United Kingdom. 
  • Among EU5 countries, Italy had the highest number of diagnosed prevalent cases for AS (191,566 cases), while UK had the least cases (54,634) in 2021.
  • Total diagnosed prevalent cases of Ankylosing Spondylitis in Japan was found to be 4,095 in the year 2021.

Scope of the Report

  • The report covers the descriptive overview of AS, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the historical and forecasted patient pool covering the 7MM countries. (US, EU5, Japan)
  • The report assesses the disease risk and burden and highlights the unmet needs of the 7MM countries.
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM countries by Total Prevalent cases of Ankylosing Spondylitis, Diagnosed Prevalent cases of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis

Report Highlights

  • 11-Year Forecast of AS
  • 7MM Coverage 
  • Total Prevalent cases of Ankylosing Spondylitis
  • Diagnosed Prevalent cases of Ankylosing Spondylitis
  • Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis
  • Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis
  • Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis

Key Questions Answered

  • What are the disease risk, and burden of AS?
  • What is the historical AS patient pool in the 7MM countries?
  • What would be the forecasted patient pool of AS at the 7MM level?
  • What will be the growth opportunities across the 7MM countries with respect to the patient population pertaining to AS?
  • At what CAGR the population is expected to grow across the 7MM countries during the forecast period (2022–2032)?

Reasons to buy

The AS report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM AS epidemiology forecast.
  • The AS epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The AS epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation 
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Ankylosing Spondylitis (AS) Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Ankylosing Spondylitis (AS) in 2019

3.2. Patient Share (%) Distribution of Ankylosing Spondylitis (AS) in 2032

4. Executive Summary of Ankylosing Spondylitis (AS)

5. Ankylosing Spondyloarthritis (AS): Future Prospects

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Severity based classification

7.2.1. Mild or early ankylosing spondylitis

7.2.2. Severe or advanced AS

7.3. Biology and pathology of AS

7.4. Etiology

7.4.1. Endogenous Factors

7.4.2. Exogenous Factors

7.5. Risk Factors of AS

7.5.1. Gender

7.5.2. Family History

7.5.3. Genetic Predisposition

7.5.4. Age

7.5.5. Signs and symptoms of AS

7.6. Genetics of ankylosing spondylitis — insights into pathogenesis

7.6.1. HLAB27 causing AS:

7.6.2. Antigen processing and presentation

7.6.3. IL-17 and type 3 immunity in AS

7.6.4. IL-17

7.6.4.1. γδ T cells:

7.6.4.2. KIR3DL2+ T cells:

7.6.4.3. NKT cells:

7.6.4.4. Mast cells and neutrophils:

7.6.4.5. CD4 and CD8 T-cells:

7.6.5. IL-23 signaling

7.6.6. Targeting type-3 immunity in AS

7.7. Biomarkers

7.7.1. Genetic biomarkers

7.7.2. Markers for inflammation

7.7.3. Cartilage Turnover Markers

7.7.4. Other Biomarkers

7.8. Diagnosis

7.8.1. Examination

7.8.2. Genetics

7.8.3. Laboratory Findings

7.8.4. Imaging

7.8.5. Osteoporosis and Fracture

7.8.6. Observation

7.8.7. Mobility Testing

7.8.8. Strength Testing

7.8.9. Spine examination

7.9. Diagnostic Criteria

7.9.1. New York Classification Criteria: Diagnostic Criteria

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Epidemiology Methodology

8.3. Total Prevalent Cases of Ankylosing Spondylitis (AS) in the 7MM

8.4. Diagnosed Prevalent Cases of Ankylosing Spondylitis (AS) in the 7MM

8.5. Epidemiology of Ankylosing Spondylitis (AS)

8.6. The United States

8.6.1. Total Prevalent Cases of Ankylosing Spondylitis in the United States

8.6.2. Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United States

8.6.3. Gender-specific Diagnosed Prevalent Cases of Ankylosing spondylitis in the United States

8.6.4. Age-specific Diagnosed Prevalent Cases of Ankylosing spondylitis in the United States

8.6.5. Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United States

8.7. EU5

8.7.1. Total Prevalent Cases of Ankylosing Spondylitis in the EU5

8.7.2. Diagnosed Prevalent Cases of Ankylosing Spondylitis in the EU5

8.7.3. Gender-specific Diagnosed Prevalent Cases of Ankylosing spondylitis in the EU5

8.7.4. Age-specific Diagnosed Prevalent Cases of Ankylosing spondylitis in the EU5

8.7.5. Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the EU5

8.8. Japan

8.8.1. Total Prevalent Cases of Ankylosing Spondylitis in Japan

8.8.2. Diagnosed Prevalent Cases of Ankylosing Spondylitis in Japan

8.8.3. Gender-specific Prevalent Cases of Ankylosing Spondylitis (AS) in Japan

8.8.4. Age-specific Diagnosed Prevalent Cases of Ankylosing spondylitis in Japan

8.8.5. Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in Japan

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Summary of AS Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Genetic Associations with AS

Table 4: Principles of Management of AS

Table 5: Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial

Table 6: Total Prevalent Population of Ankylosing Spondylitis (AS) in the 7MM (2019–2032)

Table 7: Diagnosed Prevalent Cases of Ankylosing Spondylitis (AS) in the 7MM (2019–2032)

Table 8: Total Prevalent Cases of Ankylosing Spondylitis in the United State (2019–2032)

Table 9: Diagnosed Prevalent Cases of AS in the United States (2019–2032)

Table 10: Gender-specific Diagnosed Prevalent Cases of AS in the US (2019–2032)

Table 11: Age-specific Diagnosed Prevalent Cases of AS in the US (2019–2032)

Table 12: Gene-specific Diagnosed Prevalent Cases of AS in the US (2019–2032)

Table 13: Total Prevalent Cases of Ankylosing Spondylitis in the EU5 (2019–2032)

Table 14: Diagnosed Prevalent Cases of AS in EU-5 (2019–2032)

Table 15: Gender-specific Diagnosed Prevalent Cases of AS in EU-5 (2019–2032)

Table 16: Age-specific Diagnosed Prevalent Cases of AS in EU5 (2019–2032)

Table 17: Type-specific Diagnosed Prevalent Cases of AS in EU5 (2019–2032)

Table 18: Prevalent Cases of AS in Japan (2019–2032)

Table 19: Diagnosed Prevalent Cases of AS in Japan (2019–2032)

Table 20: Gender-specific Diagnosed Prevalent Cases of AS in Japan (2019–2032)

Table 21: Age-specific Diagnosed Prevalent Cases of AS in Japan (2019–2032)

Table 22: Type-specific Diagnosed Prevalent Cases of AS in Japan (2019–2032)

List of Figures

Figure 1: Possible Complications of Ankylosing Spondylitis

Figure 2: Management of Ankylosing Spondylitis (AS)

Figure 3: Risk Factors for AS

Figure 4: Functional roles of AS-associated genes

Figure 5: Antigen processing and presentation: potential link to AS

Figure 6: Multiple roles for HLA-B27 in the pathogenesis of Ankylosing spondylitis

Figure 7: Immune cells involved in the initiation, progression, and regulation of AS

Figure 8: The role of the gut in driving joint inflammation in AS

Figure 9: Potential mechanisms by which ERAP variants operate to influence disease risk in AS

Figure 10: ASAS classification criteria for axial and peripheral spondyloarthritis

Figure 11: Total Prevalent Cases of Ankylosing Spondylitis (AS) in the 7MM (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Ankylosing Spondylitis (AS) in the 7MM (2019–2032)

Figure 13: Total Prevalent Cases of Ankylosing Spondylitis in the United States (2019-2032)

Figure 14: Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United States (2019-2032)

Figure 15: Gender-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United Stat

Figure 16: Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United States

Figure 17: Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the United States

Figure 18: Total Prevalent Cases of Ankylosing Spondylitis in the EU5 (2019–2032)

Figure 19: Diagnosed Prevalent Cases of Ankylosing Spondylitis (AS) in EU5 (2019–2032)

Figure 20: Gender-specific Prevalent Cases of Ankylosing Spondylitis (AS) in EU5 (2019–2032)

Figure 21: Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in EU5 (2019-2032)

Figure 22: Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in the EU5 (2019-2032)

Figure 23: Total Prevalent Cases of Ankylosing Spondylitis (AS) in Japan (2019–2032)

Figure 24: Diagnosed Prevalent Cases of Ankylosing Spondylitis in Japan (2019-2032)

Figure 25: Gender-specific Prevalent Cases of Ankylosing Spondylitis (AS) in Japan (2019-2032)

Figure 26: Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in Japan (2019-2032)

Figure 27: Gene-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in Japan (2019-2032)

Forward to Friend

Need A Quote